Abstract: The invention concerns a method for purifying the Helicobacter adhesin-like protein A (AlpA) which consists in: (i) contacting an AlpA preparation and 2.5 to 3.5 M of guanidine with a hydrophobic interaction chromatography material, so that the AlpA is adsorbed on the material; and (ii) eluting the AlpA with a solution containing 3.5 to 4.5 M of guanidine. The AlpA preparation to be purified can be in particular derived from an E. coli culture capable of expressing AlpA in a high-level recombinant form, rAlpA being in the form of inclusion bodies, the latter being recovered and solubilized in the presence of guanidine, and optionally ammonium sulphate-precipitated for the purpose of preliminary purification. The hydrophobic interaction chromatography can be followed up by an anion exchange chromatography in the presence of 8 M of urea.

Abstract: The invention provides Helicobacter polypeptides, designated GHPO 1360 and GHPO 750, which can be used in vaccination methods for preventing or treating Helicobacter infection, and polynucleotides that encode these polypeptides.

Abstract: The invention relates to proteins of Helicobacter pylori, in a substantially purified forms, that can be obtained from a membrane fraction of H. pylori and of which the molecular weights after electrophoresis on a 10% polyacrylamide gel in the presence of SDS are approximately 54, 50, 32-35, or 30 kDa.

Abstract: The invention provides 76 kDa Helicobacter polypeptides, which can be used in vaccination methods for preventing or treating Helicobacter infection, and polynucleotides that encode these polypeptides.

Abstract: The invention provides Helicobacter polypeptides, designated GHPO 1360 and GHPO 750, which can be used in vaccination methods for preventing or treating Helicobacter infection, and polynucleotides that encode these polypeptides.

Abstract: The prevention and treatment of gastric infections caused by the bacterium Helicobacter are disclosed. A newly identified cell-surface protein purified from Helicobacter, and the use thereof as a vaccine, are also disclosed. Said protein is able to bind to human lactoferrin.

Abstract: The present invention relates to the lower molecular weight subunit of the human transferrin receptor of a strain of N. meningitidis, in purified form, as well as to a vaccinal pharmaceutical composition intended for the prevention or attenuation of the effects of an N. meningitidis infection, containing the said subunit in purified form.

Abstract: The present invention relates to the lower molecular weight subunit of the human transferrin receptor of a strain of N. meningitidis, in purified form, as well as to a vaccinal pharmaceutical composition intended for the prevention or attenuation of the effects of an N. meningitidis infection, containing the said subunit in purified form.